Nucynta doses. Nucynta Dosage Guide: Comprehensive Overview for Effective and Safe Pain Management
What are the proper Nucynta dosages? How to initiate treatment and adjust dosage for optimal pain relief? Get answers to these questions and more in this detailed Nucynta dosage guide.
Nucynta Dosage: Key Considerations for Effective Pain Management
Nucynta (tapentadol) is a potent opioid analgesic used for the management of moderate to severe acute pain. Establishing the appropriate Nucynta dosage is crucial for ensuring effective pain relief while minimizing the risk of adverse effects. This comprehensive dosage guide provides healthcare professionals and patients with the necessary information to navigate the safe and effective use of Nucynta.
Initiating Nucynta Treatment: Dosing Recommendations
The initial dosage of Nucynta should be individualized based on the patient’s pain severity, response to previous analgesic treatment, and risk factors for addiction, abuse, and misuse. The recommended starting dose of Nucynta is 50 mg to 100 mg every 4 to 6 hours as needed for pain relief. On the first day of treatment, the second dose may be administered as soon as one hour after the first dose if adequate pain relief is not achieved.
Subsequent dosing should be adjusted to maintain adequate analgesia with acceptable tolerability, typically in the range of 50 mg, 75 mg, or 100 mg every 4 to 6 hours. It is important to note that daily doses greater than 700 mg on the first day and 600 mg on subsequent days have not been studied and are not recommended.
Dose Adjustments for Patients with Hepatic Impairment
The safety and efficacy of Nucynta in patients with severe hepatic impairment (Child-Pugh Score 10-15) have not been studied, and the use of Nucynta in this population is not recommended.
For patients with moderate hepatic impairment (Child-Pugh Score 7 to 9), the initial dosage of Nucynta should be reduced to 50 mg, administered no more frequently than once every 8 hours (maximum of three doses in 24 hours). Further dosage adjustments should be made to maintain analgesia with acceptable tolerability, either by shortening or lengthening the dosing interval. Close monitoring for respiratory and central nervous system depression is recommended in this patient population.
No dosage adjustment is required for patients with mild hepatic impairment (Child-Pugh Score 5 to 6).
Titration and Maintenance of Nucynta Therapy
Patients receiving Nucynta should be continuously reevaluated to assess the maintenance of pain control and the relative incidence of adverse reactions. Frequent communication among the prescriber, healthcare team, patient, and caregiver/family is important during periods of changing analgesic requirements, including initial titration.
If the level of pain increases after dosage stabilization, the healthcare team should attempt to identify the source of the increased pain before increasing the Nucynta dosage. If unacceptable opioid-related adverse reactions are observed, the dosage should be reduced to obtain an appropriate balance between pain management and opioid-related adverse effects.
Patient Access to Naloxone for Opioid Overdose Emergency
Clinicians should discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver, and assess the potential need for access to naloxone, both when initiating and renewing treatment with Nucynta. Patients and caregivers should be informed about the various ways to obtain naloxone, as permitted by individual state naloxone dispensing and prescribing requirements or guidelines.
Clinicians should consider prescribing naloxone based on the patient’s risk factors for overdose, such as concomitant use of central nervous system (CNS) depressants, a history of opioid use disorder, or prior opioid overdose. The presence of risk factors for overdose should not prevent the proper management of pain in any given patient.
Conclusion
The appropriate Nucynta dosage is essential for effective pain management while minimizing the risk of adverse effects. By following the dosing recommendations, titrating the dosage, and considering patient-specific factors, healthcare professionals can ensure the safe and effective use of Nucynta for their patients. Regular communication, close monitoring, and proactive measures, such as discussing naloxone access, are crucial elements in the successful management of pain with Nucynta.
Nucynta Dosage Guide – Drugs.com
Save
Generic name: TAPENTADOL HYDROCHLORIDE 50mg
Dosage form: tablet, film coated
Drug class: Opioids (narcotic analgesics)
Medically reviewed by Drugs.com. Last updated on Mar 6, 2023.
Important Dosage and Administration Instructions
Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5)].
Initiate the dosing regimen for each patient individually, taking into account the patient’s severity of pain, patient response, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse [see Warnings and Precautions (5.1)].
Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy and following dosage increases with NUCYNTA and adjust the dosage accordingly [see Warnings and Precautions (5.3)]
Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose
Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with NUCYNTA tablets [see Warnings and Precautions (5.
3), Patient Counseling Information (17)].
Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program).
Consider prescribing naloxone, based on the patient’s risk factors for overdose, such as concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose. The presence of risk factors for overdose should not prevent the proper management of pain in any given patient [see Warnings and Precautions (5.1, 5.3, 5.5)].
Consider prescribing naloxone if the patient has household members (including children) or other close contacts at risk for accidental ingestion or overdose.
Initial Dosage
Initiating Treatment with NUCYNTA Tablets
Initiate treatment with NUCYNTA tablets in a dosing range of 50 mg to 100 mg every 4 to 6 hours as needed for pain.
On the first day of dosing, the second dose may be administered as soon as one hour after the first dose, if adequate pain relief is not attained with the first dose. Subsequent dosing is 50 mg, 75 mg, or 100 mg every 4 to 6 hours and should be adjusted to maintain adequate analgesia with acceptable tolerability.
Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not been studied and are not recommended.
NUCYNTA tablets may be given with or without food [see Clinical Pharmacology (12.3)].
Conversion from NUCYNTA Tablets to NUCYNTA ER
Patients can be converted from NUCYNTA tablets to NUCYNTA ER using the equivalent total daily dose of NUCYNTA tablets and dividing it into two equal doses of NUCYNTA ER separated by approximately 12-hour intervals. As an example, a patient receiving 50 mg of NUCYNTA tablets four times per day (200 mg/day) may be converted to 100 mg NUCYNTA ER twice a day.
Dosage Modifications in Patients with Hepatic Impairment
The safety and efficacy of NUCYNTA tablets has not been studied in patients with severe hepatic impairment (Child-Pugh Score 10-15) and use in this population is not recommended [see Warnings and Precautions (5.
16)].
Initiate treatment of patients with moderate hepatic impairment (Child-Pugh Score 7 to 9) with 50 mg no more frequently than once every 8 hours (maximum of three doses in 24 hours). Further treatment should reflect maintenance of analgesia with acceptable tolerability, to be achieved by either shortening or lengthening the dosing interval. Monitor closely for respiratory and central nervous system depression [see Clinical Pharmacology (12.3)].
No dosage adjustment is recommended in patients with mild hepatic impairment (Child-Pugh Score 5 to 6) [see Clinical Pharmacology (12.3)].
Titration and Maintenance of Therapy
Continually reevaluate patients receiving NUCYNTA tablets to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse [see Warnings and Precautions (5.1)]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.
If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the NUCYNTA tablets dosage. If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.
Safe Reduction or Discontinuation of NUCYNTA Tablets
Do not abruptly discontinue NUCYNTA Tablets in patients who may be physically dependent on opioids. Rapid discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.
When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking NUCYNTA Tablets, there are a variety of factors that should be considered, including the dose of NUCYNTA Tablets the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient.
It is important to ensure ongoing care of the patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic. When opioid analgesics are being discontinued due to a suspected substance use disorder, evaluate and treat the patient, or refer for evaluation and treatment of the substance use disorder. Treatment should include evidence-based approaches, such as medication assisted treatment of opioid use disorder. Complex patients with co-morbid pain and substance use disorders may benefit from referral to a specialist.
There are no standard opioid tapering schedules that are suitable for all patients. Good clinical practice dictates a patient-specific plan to taper the dose of the opioid gradually. For patients on NUCYNTA Tablets who are physically opioid-dependent, initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks.
Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper.
It may be necessary to provide the patient with lower dosage strengths to accomplish a successful taper. Reassess the patient frequently to manage pain and withdrawal symptoms, should they emerge. Common withdrawal symptoms include restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. If withdrawal symptoms arise, it may be necessary to pause the taper for a period of time or raise the dose of the opioid analgesic to the previous dose, and then proceed with a slower taper. In addition, monitor patients for any changes in mood, emergence of suicidal thoughts, or use of other substances.
When managing patients taking opioid analgesics, particularly those who have been treated for a long duration and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper.
A multimodal approach to pain management may optimize the treatment of chronic pain, as well as assist with the successful tapering of the opioid analgesic [see Warnings and Precautions (5.13), Drug Abuse and Dependence (9.3)].
More about Nucynta (tapentadol)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (273)
- Drug images
- Latest FDA alerts (1)
- Side effects
- During pregnancy
- Support group
- FDA approval history
- Drug class: Opioids (narcotic analgesics)
- Breastfeeding
- En español
Patient resources
- Drug Information
Professional resources
- Prescribing Information
Other formulations
- Nucynta ER
Related treatment guides
- Pain
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer
Nucynta ER Dosage Guide – Drugs.com
Save
Generic name: TAPENTADOL HYDROCHLORIDE 50mg
Dosage form: tablet, film coated, extended release
Drug class: Opioids (narcotic analgesics)
Medically reviewed by Drugs.com. Last updated on Mar 2, 2023.
Important Dosage and Administration Instructions
NUCYNTA ER should be prescribed only by healthcare professionals who are knowledgeable in the use of potent opioids for the management of chronic pain.
- Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5)].
- Initiate the dosing regimen for each patient individually, taking into account the patient’s severity of pain, patient response, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse [see Warnings and Precautions (5.1)]
- Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy and following dosage increases with NUCYNTA ER and adjust the dosage accordingly [see Warnings and Precautions (5.
3)].
3)].Instruct patients to swallow NUCYNTA ER tablets whole, one tablet at a time, with enough water to ensure complete swallowing immediately after placing in the mouth [see Patient Counseling Information (17)]. Crushing, chewing, or dissolving NUCYNTA ER tablets will result in uncontrolled delivery of tapentadol and can lead to overdose or death [see Warnings and Precautions (5.1)].
Discontinue all other tapentadol and tramadol products when beginning and while taking NUCYNTA ER [see Warnings and Precautions (5.7)]. Although the maximum approved total daily dose of NUCYNTA immediate-release formulation is 600 mg per day, the maximum total daily dose of NUCYNTA ER is 500 mg. Do not exceed a total daily dose of NUCYNTA ER of 500 mg.
Patient Access to Naloxone for the Emergency Treatment of Opioid Overdose
Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver and assess the potential need for access to naloxone, both when initiating and renewing treatment with NUCYNTA ER [see Warnings and Precautions (5.
3), Patient Counseling Information (17)].
Inform patients and caregivers about the various ways to obtain naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program).
Consider prescribing naloxone, based on the patient’s risk factors for overdose, such as concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose. The presence of risk factors for overdose should not prevent the proper management of pain in any given patient [see Warnings and Precautions (5.1, 5.3, 5.5)].
Consider prescribing naloxone if the patient has household members (including children) or other close contacts at risk for accidental ingestion or overdose.
Initial Dosage
Use of NUCYNTA ER as the First Opioid Analgesic (opioid-naïve patients)
Initiate treatment with NUCYNTA ER with the 50 mg tablet orally twice daily (approximately every 12 hours).
Use of NUCYNTA ER in Patients who are not Opioid Tolerant
The starting dose for patients who are not opioid tolerant is NUCYNTA ER 50 mg orally twice daily (approximately every 12 hours). Use of higher starting doses in patients who are not opioid tolerant may cause fatal respiratory depression.
Conversion from NUCYNTA to NUCYNTA ER
Patients can be converted from NUCYNTA to NUCYNTA ER using the equivalent total daily dose of NUCYNTA and dividing it into two equal doses of NUCYNTA ER separated by approximately 12-hour intervals. As an example, a patient receiving 50 mg of NUCYNTA four times per day (200 mg/day) may be converted to 100 mg NUCYNTA ER twice a day.
Conversion from Other Opioids to NUCYNTA ER
There are no established conversion ratios for conversion from other opioids to NUCYNTA ER defined by clinical trials. Initiate dosing using NUCYNTA ER 50 mg orally every 12 hours.
It is safer to underestimate a patient’s 24-hour oral tapentadol dosage and provide rescue medication (e.
g., immediate-release opioid) than to overestimate the 24-hour oral tapentadol requirements which could result in an adverse reaction due to an overdose. While useful tables of opioid equivalents are readily available, there is inter-patient variability in the potency of opioid drugs and opioid formulations.
Close observation and frequent titration are warranted until pain management is stable on the new opioid. Monitor patients for signs and symptoms of opioid withdrawal and for signs of oversedation/toxicity after converting patients to NUCYNTA ER.
Conversion from Methadone to NUCYNTA ER
Close monitoring is of particular importance when converting from methadone to other opioid agonists. The ratio between methadone and other opioid agonists may vary widely as a function of previous dose exposure. Methadone has a long half-life and can accumulate in the plasma.
Titration and Maintenance of Therapy
Individually titrate NUCYNTA ER to a dose that provides adequate analgesia and minimizes adverse reactions.
Continually reevaluate patients receiving NUCYNTA ER to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse [see Warnings and Precautions (5.1)]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration. During chronic therapy, periodically reassess the continued need for opioid analgesics.
Patients who experience breakthrough pain may require a dosage adjustment of NUCYNTA ER, or may need rescue medication with an appropriate dose of an immediate-release analgesic. If the level of pain increases after dose stabilization, attempt to identify the source of increased pain before increasing the NUCYNTA ER dosage. Titrate patients to adequate analgesia with dose increases of 50 mg no more than twice daily every three days. In clinical studies, efficacy with NUCYNTA ER was demonstrated relative to placebo in the dosage range of 100 mg to 250 mg twice daily [see Clinical Studies (14)].
If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.
Dosage Modification in Patients with Hepatic Impairment
The use of NUCYNTA ER in patients with severe hepatic impairment (Child-Pugh Score 10-15) is not recommended [see Warnings and Precautions (5.15)].
In patients with moderate hepatic impairment (Child-Pugh Score 7 to 9), initiate treatment using 50 mg NUCYNTA ER, administer no more frequently than once every 24 hours, and monitor closely for respiratory and central nervous system depression, particularly during initiation and titration of NUCYNTA ER. The maximum recommended dose for patients with moderate hepatic impairment is 100 mg of NUCYNTA ER per day. Monitor closely for respiratory and central nervous system depression [see Clinical Pharmacology (12.2)].
No dosage adjustment is recommended in patients with mild hepatic impairment (Child-Pugh Score 5 to 6) [see Warnings and Precautions (5.
15), Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].
Safe Reduction or Discontinuation of NUCYNTA ER
Do not abruptly discontinue NUCYNTA ER in patients who may be physically dependent on opioids. Rapid discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.
When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking NUCYNTA ER, there are a variety of factors that should be considered, including the dose of NUCYNTA ER the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient.
It is important to ensure ongoing care of the patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic. When opioid analgesics are being discontinued due to a suspected substance use disorder, evaluate and treat the patient, or refer for evaluation and treatment of the substance use disorder. Treatment should include evidence-based approaches, such as medication assisted treatment of opioid use disorder. Complex patients with comorbid pain and substance use disorders may benefit from referral to a specialist.
There are no standard opioid tapering schedules that are suitable for all patients. Good clinical practice dictates a patient-specific plan to taper the dose of the opioid gradually. For patients on NUCYNTA ER who are physically opioid-dependent, initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks.
Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper.
It may be necessary to provide the patient with lower dosage strengths to accomplish a successful taper. Reassess the patient frequently to manage pain and withdrawal symptoms, should they emerge. Common withdrawal symptoms include restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. If withdrawal symptoms arise, it may be necessary to pause the taper for a period of time or raise the dose of the opioid analgesic to the previous dose, and then proceed with a slower taper. In addition, monitor patients for any changes in mood, emergence of suicidal thoughts, or use of other substances.
When managing patients taking opioid analgesics, particularly those who have been treated for a long duration and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper.
A multimodal approach to pain management may optimize the treatment of chronic pain, as well as assist with the successful tapering of the opioid analgesic [see Warnings and Precautions (5.13), Drug Abuse and Dependence (9.3)].
Frequently asked questions
- What does XR or ER mean after a drug name?
More about Nucynta ER (tapentadol)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (81)
- Drug images
- Latest FDA alerts (1)
- Side effects
- During pregnancy
- Drug class: Opioids (narcotic analgesics)
- Breastfeeding
- En español
Patient resources
- Drug Information
- Nucynta ER (Advanced Reading)
Professional resources
- Prescribing Information
Other formulations
- Nucynta
Related treatment guides
- Pain
- Diabetic Peripheral Neuropathy
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer
Nucynta Solution / Nucynta Solution in English – Product
Nucynta Solution / Nucynta Solution in English – Product – Medicine.net
About Us
- About Us
Privacy Policy 90 006 Terms of use
Medicine.net
- Overview
- Benefits
- Side effects
- Precautions
- Interactions
- Contraindications
Overview
Nucynta Solution is used for moderate to severe acute pain, severe neuropathic pain and other conditions.
Nucynta Solution contains the following active ingredients: Tapentadol Hydrochloride. Available in solution form.
Detailed information regarding the use, composition, dosage, side effects of Nucynta Solution / Nucynta Solution, as well as user reviews are provided below:
Uses
Nucynta Solution / Nucynta Solution is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms:
- Moderate to severe acute pain
- Severe neuropathic pain
Learn more: Uses
Side Effects
The following is a list of possible side effects that may be caused by the constituents of Nucynta Solution.
This list is not final. These side effects have been recorded previously, but are not always recorded when using the drug. Some of these side effects may be extremely rare, but have incredibly severe consequences. If you notice any side effects, contact your doctor immediately. Especially in the case of observing side effects for a long time.
- Nausea
- Vomiting
- Loss of appetite
- Headache
- Heartburn
- Diarrhea
- Abdominal pain
- Dry mouth
- Dizziness
- Excessive fatigue
- Anxiety
- Drowsiness
with side effects not listed above, contact your healthcare provider for advice. In addition, you can report side effects to your local Food and Drug Administration.
Precautions
Before starting this drug, tell your doctor about any medications you are taking, dietary supplements (such as vitamins, natural supplements, etc.), allergies, existing medical conditions, and current health conditions (such as pregnancy, upcoming surgery, and etc.
). The side effects of the drug may be more pronounced depending on the state of your body. Take this medicine as directed by your doctor, or follow the directions for use that come with your medicine. The dosage of the drug depends on your condition. Tell your doctor if there is no change or if your condition worsens. Important points to discuss with your healthcare provider are listed below.
- Liver disease
- Kidney disease
- Breastfeeding
- Blockage in the stomach or intestines
- Difficulty urinating
- Having surgery
- gallbladder disease
- pancreatic disease
- thyroid disease
If if you use other drugs or over the counter products at the same time, the effects of Nucinta Solution may change. Tell your healthcare provider about all medications, vitamins, and supplements you use. Your doctor will be able to make the right plan for taking the drug, which will avoid negative interactions.
Nucinta Solution / Nucynta Solution may interact with the following drugs and products:
- Almotriptan
- Buprenorphine
- Butorphanol
- Citalopram \ Escitalopram
- Doxepin
- Eletriptan
- Fluoxetine
- Fluvoxamine
- Frovatriptan
- Imipramine
Composition and active ingredients ingredients (salts)
- Tapentadol Hydrochloride
Please note that this preparation is available in different strengths for each of the active ingredients listed above.
Packing options and strengths
Nucynta Solution is available in the following pack strengths
Nucynta Solution / Nucynta Solution packs are available: EQ 20MG BASE/ML
FAQ
Is it safe to drive or operate heavy machinery while using this product?
If you experience drowsiness, dizziness, hypotension or a headache as side-effects when using Nucynta Solution medicine then it may not be safe to drive a vehicle or operate heavy machinery.
You should stop driving if taking this medicine makes you drowsy, dizzy, or hypotensive. Doctors recommend that you stop drinking alcohol with such drugs, because. alcohol greatly increases the side effects and drowsiness. Please check for these effects on your body when using Nucynta Solution. Be sure to consult your doctor for advice based on the characteristics of your body and general health.Is this drug (product) addictive or addictive?
Most drugs are not habit-forming or addictive. In most cases, the state classifies drugs that can be addictive as controlled dispensing drugs. For example, schedule H or X in India and schedule II-V in the USA. Please check the information on the drug packaging to make sure that this drug is not in the controlled category. Also, do not self-medicate or accustom your body to medications without consulting your doctor.
Can I stop using this product immediately or do I need to slowly stop using it?
Some medications need to be stopped gradually due to a rebound effect.
Be sure to consult your healthcare provider for advice based on your body, general health, and other medications you may be taking.
You should stop driving if taking this medicine makes you drowsy, dizzy, or hypotensive. Doctors recommend that you stop drinking alcohol with such drugs, because. alcohol greatly increases the side effects and drowsiness. Please check for these effects on your body when using Nucynta Solution. Be sure to consult your doctor for advice based on the characteristics of your body and general health.
Be sure to consult your healthcare provider for advice based on your body, general health, and other medications you may be taking.Cite this page
Page URL
HTML Link
Nucynta Solution
APA Style Citation
- Nucynta Solution – Medicine.net. (n.d.). Retrieved March 15, 2023, from https://www.Medication.net/us-ru/nucynta-solution
MLA Style Citation
- .com . N.p., n.d. Web. 15 Mar. 2023.
Chicago Style Citation
- Nucynta Solution Tabletwise. Accessed March 15, 2023. https://www.drug.net/us-ru/nucynta-solution.
More information about Nucinta Solution / Nucynta Solution
- Uses of
- Reviews
- What are the uses of Nucinta Solution / Nucynta Solution?
- What are the side effects of Nucinta Solution / Nucynta Solution?
- What other medicines does Nucynta Solution interact with?
- When should you not take Nucynta Solution?
- What precautions should you take while using Nucynta Solution?
Last update date
This page was updated on 9/27/2020.
This page provides information for Nucynta Solution Product in English .
Share with friends, get 20% off
Invite your friends to TabletWise learning marketplace. For each purchase they make, you get 20% off (upto $10) on your next purchase.
Nucynta vs. Oxycodone: Differences, Similarities & What’s Best for You – Drug Vs. Friend
Home >> Drug Vs. Friend >> Nucynta vs Oxycodone: Differences, Similarities & Which is Best for You
Drug Vs. Friend
Drug Overview and Key Differences | Conditions of treatment | Efficiency | Insurance coverage and cost comparison | Side effects | Drug Interactions | Warnings | FAQ
Nucynta and oxycodone are FDA approved. opioid prescription medications indicated for the treatment of severe, acute pain. They are typically used for pain that cannot be controlled with non-opioid medications or when the patient is intolerant of other alternatives. Both painkillers are classified as narcotic (Appendix II), which means they have a high potential for abuse or dependence.
How Nucynta works is not fully understood. Some studies have shown that Nucynta is a mu-receptor (nociceptor) agonist and norepinephrine reuptake inhibitor, resulting in pain relief. Oxycodone works by binding to mu receptors in the brain, which dampens or blocks pain signals, resulting in pain relief.
Since both drugs are very strong, they are usually used in situations where pain relief is required when lighter (non-narcotic) pain medications would not be effective or would not be tolerated. Although both drugs are used for severe pain, they have many differences, which we will discuss below.
What is the main difference between Nucynta and oxycodone?
Nucinta (tapentadol) is an opioid or narcotic pain reliever (painkiller). It is available branded as both immediate-release and extended-release tablets.
The extended release tablet is called Nucynta ER. The starting dose is 50 to 100 mg every four to six hours as needed for pain. The dose may be changed by your doctor and the maximum dose is 600 mg per day.
Oxycodone is also a general opioid analgesic (and immediate release oxycodone IR) and is available in branded form as OxyContin, an extended release tablet. Dosage varies, but a typical dose for immediate release oxycodone tablets is 5 to 15 mg every four to six hours depending on the pain.
| Main differences between Nucynta and oxycodone | ||
|---|---|---|
| Nucynta | Oxycodone | |
| Drug class | Opioid (narcotic) analgesic | Opioid (narcotic) analgesic |
| Brand/generic status | Brand | Brand and generic |
| What is a generic/trademark? | Generic: Tapentadol | Brand: OxyIR (immediate release), Oxycontin (long acting) |
| What form(s) does the drug come in? | Immediate-release tablet Extended-release tablet | Immediate-release tablet Immediate-release capsule Extended-release tablet Oral solution |
| What is the standard dosage? | Initial: 50 to 100 mg every 4 to 6 hours as needed.  If necessary, the dose can be adjusted by the doctor. Maximum 700 mg per day on the first day of treatment, then the maximum dose is 600 mg per day after the first day. | Immediate release tablet: 5-15 mg every 4-6 hours as needed Extended-release tablet: 20 mg every 12 hours |
| How long does a typical treatment last? | Short-term, may be used longer depending on condition treated (eg chronic pain) and response | Short-term, may be used longer depending on condition treated (eg chronic pain) and response |
| Who usually takes this medicine? | Adults | Adults |
Want the best price on Nucynta?
Sign up for Nucynta Price Alerts and be notified when prices change!
Receive price alerts
Conditions treated by Nucynta and oxycodone
Both Nucynta and oxycodone have the same indication for treatment, which is to treat acute adult pain that is severe enough to require an opioid analgesic, and when alternative therapies are inadequate or intolerable.
| Condition | Nucynta | Oxycodone |
| yes | yes |
Nucynta or oxycodone more effective?
In a study comparing immediate release Nucynta with immediate release oxycodone in patients with moderate to severe acute back pain, both drugs were equally safe and effective in treating back pain as well as associated leg pain. Nucynta patients had fewer stomach-related side effects.
In a study comparing the potential for abuse in patients taking Nucynta or oxycodone, Nucynta was found to have less potential for abuse.
The most effective medicine for you should only be determined by your doctor, who will review your condition(s), medical history and other medicines you are taking.
Coverage and cost comparison of Nucynta and oxycodone
State law states that if you are taking an opioid pain reliever for the first time, it is likely that you will receive a small amount.
Insurance coverage varies by Nucynta. Because it is more expensive and only available under brand names, your copay may be higher or the drug may need prior authorization from your insurance company. Nucynta is generally not covered by Medicare Part D. Nucynta 50mg, 30 tablets usually cost around $250, but you can get it for as little as $211 with the SingleCare discount.
Oxycodone is usually covered by insurance and Part D. Medicare. The cash price of 30.5mg tablets can be around $100, but you can use a single coupon at participating pharmacies and get it from $36.
| Nucynta | Oxycodone | |
| Usually covered by insurance? | Varies | yes |
| Usually covered by Medicare Part D? | No | yes |
| Standard dosage0283 5 mg #30 tablets | ||
| Typical Medicare Part D copay | $95-482 | $2-56 |
| SingleCare Cost | $211+ | 36-62 US$ |
Common side effects of Nucynta versus oxycodone
The most common side effects of Nucynta are nausea, vomiting, drowsiness, dizziness, constipation, dry mouth and itching.
Severe respiratory depression (slowed breathing, lack of oxygen) may occur, which can be life-threatening or fatal.
Exact percentages of oxycodone not reported, except that side effects were observed in more than or equal to 3% of patients. The most common side effects are nausea, constipation, vomiting, headache, itching (itching), insomnia, dizziness, weakness, and drowsiness. Serious adverse reactions may include respiratory depression, respiratory arrest (breathing arrest), cardiac arrest (sudden loss of heart, breathing, and consciousness function), low blood pressure, and/or shock.
Because of the serious risks, it is very important that if you are taking Nucynta or oxycodone, you take the drug exactly as prescribed and do not take extra doses. You should also monitor respiratory depression, especially when you start taking one of these drugs or during a dose change.
Other side effects may occur. Check with your healthcare provider for a complete list of side effects.
| Nucynta | Oxycodone | |||
| Side effect | 90 055 Applicable? | Frequency | Applicable? | Frequency |
| 6 | ||||
| Vomiting | yes | 18% 9 | ≥3% | |
| Constipation | yes | 8% | yes | ≥3% |
| Dry mouth | yes | 4% | yes | % not reported |
| Drowsiness | yes | fifteen% | yes | ≥3% |
| Dizziness | 24% | yes | ≥3% | |
| Itching | yes | 5% | yes | ≥3% |
Source: DailyMed (Nucynta), DailyMed (oxycodone )
Nucynta drug interaction with oxycodone
Use of benzodiazepines or other CNS depressants, including other opioid drugs when combined with Nucynta or oxycodone may result in low blood pressure, respiratory depression, severe sedation, coma and/or death.
Combinations should be avoided. However, if no other option is available, the lowest dose of each drug should be used for the shortest period of time, and the patient should be closely monitored, especially at the start of treatment and any dose changes.
Taking Nucynta or oxycodone with drugs that increase serotonin levels may also increase the risk of serotonin syndrome, a life-threatening condition caused by the accumulation of too much serotonin. These drugs include antidepressants such as serotonin reuptake inhibitors, muscle relaxants, MAO inhibitors (MAO inhibitors should not be used within 14 days of taking Nucynta or oxycodone), and triptans for migraine.
Taking oxycodone with certain drugs that are metabolized by CYP3A4 or CYP2D6 may lead to drug interactions. These drugs are known as enzyme inhibitors and include macrolide antibiotics, azole antifungals, and protease inhibitors. Using them along with oxycodone can lead to high levels of the opioid, which can be very dangerous.
These drugs interact with oxycodone but not with Nucynta.
Other drugs, known as enzyme inducers, work in the opposite way to inhibitors, lowering opioid levels so that they are not as effective or may even cause withdrawal symptoms. Inducers may affect Nucynta or oxycodone.
Consult your healthcare professional for a complete list of drug interactions.
| Drug | Drug class | Nucynta | Oxycodone |
| Alprazolam Clonazepam Diazepam Lorazepam | Benzodiazepines | yes | yes |
| Alcohol | Alcohol | yes | yes |
| Codeine Fentanyl 9026 0 Hydrocodone Hydromorphone Methadone Morphine Tramadol | Opioids | yes | yes |
| Baclofen Carisoprodol Cyclobenzaprine Metaxalone Tizanidine | Muscle relaxants | yes | yes |
| Antidepressants | yes | yes | |
| Phenelzine Rasagiline Selegiline Tranylcypromine | MAO inhibitors | yes | yes |
| Furosemide Hydrochlorothiazide | Diuretics | yes | yes | Benztropine Diphenhydramine Oxybutynin Tolterodine | Anticholinergics | yes | yes |
| Almotriptan 902 60 Eletriptan Rizatriptan Sumatriptan Zolmitriptan | Triptans for migraine | yes | yes |
| Clarithromycin Erythromycin Fluconazole Ketoconazole Ritonavir | CYP3A4 or CYP2D6 inhibitors | yes | |
| Carbamazepine Phenytoin | CYP3A4 inducers | yes | yes |
The use of opioids during pregnancy, for both medical and non-medical purposes, can cause physical dependence in the baby and can lead to opioid withdrawal in the newborn shortly after birth.
Nucynta may have a lower abuse potential. Talk to your doctor if Nucynta or oxycodone is right for you, if other pain medications haven’t worked or you can’t tolerate them.